Navigation Links
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
Date:10/24/2009

LOUISVILLE, Ky., Oct. 23 /PRNewswire/ -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc. (NYSE: ACL). The agreements provide Alcon with a license to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. The agreements also provide for Alcon to acquire the shares of Potentia if specified development milestones are achieved and if Alcon elects to continue development of POT-4.

Alcon will make upfront payments to Potentia for the initial license and option rights. The agreements also provide for potential future payments to Potentia's shareholders based on the achievement of multiple clinical and global regulatory approval milestones for several therapeutic indications and on Alcon's decision to proceed with development. They also provide for sales-based royalty payments to Potentia's shareholders on any products that are ultimately approved and commercialized. Financial terms were not disclosed.

"Alcon is the proven leader in the clinical development and marketing of eye care products and compounds. We could not wish for a better company to develop POT-4 into a new treatment option for the millions of patients with macular degeneration," said Cedric Francois, President and CEO of Potentia Pharmaceuticals.

POT-4 was the first complement inhibitor to enter the clinic for ophthalmological use and is being developed as a potential treatment for both dry and wet AMD. Potentia has completed a Phase I trial for POT-4 in patients with wet AMD. The trial was designed to determine the safety and tolerability of an intravitreal injection of POT-4, as well as its stability and depot-forming properties. In the study investigators observed only minimal and mild local adverse events related to the injection with no serious adverse events related the drug itself. The study also found that POT-4 deposits form at doses of 450 microgram and greater and that the higher the concentration was the longer the deposits lasted.

"There is a body of science supporting the potential for complement inhibitors in the treatment of retinal disease," said Sabri Markabi, MD, Alcon's senior vice president of research and development and chief medical officer. "Although at a very early stage, Potentia has developed the first complement inhibitor for age-related macular degeneration and positioned it for Phase II trials and we look forward to carrying development forward with the goal of treating patients with AMD."

About POT-4

POT-4 is a complement inhibitor discovered by Dr. John Lambris of the University of Pennsylvania, a leading researcher in the field of complement. POT-4 inhibits complement factor C3 and interrupts the complement activation cascade. Complement activation can lead to local inflammation in the eye that is believed to play a pivotal role in the development of AMD. Potentia has completed a Phase I trial of POT-4 in patients with wet AMD. The rights to the technology underlying POT-4 for application outside of ophthalmology are held by Swiss-based Apellis, AG.

About AMD

AMD is the leading cause of blindness in the elderly in the western world and affects more than 10 million patients in the United States alone. Approximately 10 percent of these patients suffer from the wet form of the disease, while 90 percent suffer from the dry form. The current standard of care for wet AMD relies primarily on angiogenesis inhibitors to reduce or reverse the growth of new blood vessels and bleeding in the back of the eye. No drug has been approved for the treatment of the remaining patients who suffer from the dry form of the disease.

About Alcon

Alcon, Inc. is the world's leading eye care company, with sales of approximately $6.3 billion in 2008. Alcon, which has been dedicated to the ophthalmic industry for 65 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contacts lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon operates in 75 countries and sells products in 180 markets. Alcon's majority shareholder is Nestle, S.A., the world's largest food company. For more information on Alcon, Inc., visit the Company's web site at www.alcon.com.

About Potentia

Potentia Pharmaceuticals, Inc. is a biotechnology company focused on developing novel therapeutics to address ophthalmological diseases. HealthCare Ventures and MASA Life Science Ventures are lead institutional investors in Potentia in conjunction with a number of long-term individual investors and the Kentucky Science and Technology Corporation. Potentia is among several companies housed under the umbrella of Nucleus, Kentucky's Life Sciences & Innovation Center, established in 2008 by the University of Louisville. WilmerHale and Frost Brown Todd acted as legal advisors to Potentia.

SOURCE Potentia Pharmaceuticals


'/>"/>
SOURCE Potentia Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
2. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
3. Texas State Tests Potential New Cancer-Fighting Weapon
4. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
5. Hamon Tower Features Critical Care Advances, Potential for Reduced Costs
6. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
7. EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
8. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
9. Researchers Identify Two Genes as Potential Therapeutic Targets for Multiple Sclerosis
10. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
11. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016 KEY FINDINGS ... benefits such as reducing loss of blood during ... cardiac arrests, rapid recovery after surgeries, and decreasing ... be segmented into convective warming system, surface warming ... turn reduce the stay at hospitals thus, lowering ...
(Date:12/7/2016)... DUBLIN , Dec 7, 2016 Research ... Product, Application and End User - Global Forecast to 2021" report ... , , ... reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% ... such as the growing prevalence of cancer and rapidly increasing geriatric population ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 2016 , ... ODU, a worldwide leader in designing ... advanced highly customizable contact technology solutions. , ODU Single Contact Technology portfolio includes: ... for a wide range of applications that require customization from industries like emobility, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine ... services to families and business owners in the greater Dallas metropolitan area, is ... Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals in ...
(Date:12/7/2016)... ... 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering insurance ... launching a charity drive to raise funds that will benefit the Marine Corps League. ... and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team ...
(Date:12/7/2016)... ... December 07, 2016 , ... The ... its fully redesigned website, which launched October 17, 2016, features comprehensive information regarding ... and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... service based in Dallas, Texas, is condemning "scam operations" carried out by unethical ... to bring these scam operations to a halt. According to Texas Premier Locksmith, ...
Breaking Medicine News(10 mins):